Silent Heart attack Market, by End Use (Pharmaceutical and Biotechnology Companies, Research Centers, Healthcare IT Companies, Hospital and Clinics, Others), Application (Oncology, Molecular genetics, Nanobiotechnology, Others), Component (Hardware, Software, Input, Output): Global Opportunity Analysis and Industry Forecast, 2020-2027

The silent heart attack market was valued at $4,756.50 million in 2023 and is estimated to reach $9,971.65 million by 2033 exhibiting a CAGR of 7.7% from 2024 to 2033

Market Introduction and Definition

A silent heart attack, also known as a silent myocardial infarction (SMI), is a heart attack that occurs without the typical symptoms associated with a myocardial infarction. Unlike the more recognizable heart attack signs such as intense chest pain, shortness of breath, and sweating, silent heart attacks present with minimal or no symptoms. This can make them difficult to detect, leading to delayed treatment and diagnosis.

Silent heart attacks occur when blood flow to a part of the heart muscle is blocked, usually by a blood clot in the coronary arteries. This deprivation of oxygen-rich blood causes damage or death to the heart muscle tissue. The lack of clear symptoms means individuals may not realize they are experiencing a heart attack and may attribute mild discomfort or unusual fatigue to other less serious causes, such as indigestion or stress.

Key Takeaways

• The silent heart attack market study covers 20 countries. The research includes a segment analysis of each country in terms of value ($million) for the projected period from 2024 to 2033.
• More than 1,500 product literatures, industry releases, annual reports, and other such documents of major energy storage system industry participants along with authentic industry journals, trade associations' releases, and government websites have been reviewed for generating high-value industry insights.
• The study integrates high-quality data, professional opinions and analysis, and critical independent perspectives. The research approach intends to provide a balanced view of global markets and assist stakeholders in making informed decisions in order to achieve their most ambitious growth objectives.

Industry Trends

• On June 28, 2024, Biotricity Inc., a leading Technology-as-a-Service (TaaS) company known for its innovative medical and consumer diagnostic solutions, announced the availability of its direct-to-consumer heart health screening service, HeartSecure, for online purchase at HeartSecure.
• On June 27, 2024, Cardio Diagnostics Holdings, Inc. an AI-driven precision cardiovascular medicine company, announced that their clinical blood test, Epi+Gen CHD, became available at Family Medicine Specialists’ (FMS) retail clinic located at the Meijer Supercenter in McHenry, Illinois.

Key Market Dynamics

There has been greater investment in advanced diagnostic technologies and treatment options. This includes better access to tools such as high-resolution imaging (like MRI and CT scans) and advanced biomarker tests (like troponin levels) that can aid in the detection and diagnosis of silent heart attacks. Higher healthcare spending often correlates with improved public health awareness and the implementation of screening programs. These initiatives can lead to earlier detection of silent heart attacks, which is crucial for timely intervention and management to prevent complications. With increased expenditure, there is also improved access to specialized cardiac care facilities and professionals. This enables more accurate diagnosis, personalized treatment plans, and ongoing management strategies for patients who have experienced silent heart attacks. These factors are predicted to drive the silent heart attack market growth during the forecast period.

Silent heart attacks are often unrecognized because they lack typical symptoms. Since silent heart attacks do not present typical symptoms like chest pain, patients and even healthcare providers may not suspect a heart attack. This leads to a lack of demand for diagnostic tests designed to detect silent heart attacks. Without timely diagnosis, patients miss the window for early intervention and treatment, which affects the market for therapies aimed at preventing further damage or complications. Routine screenings often focus on symptomatic individuals or those with known risk factors. Silent heart attacks may occur in individuals without apparent risk factors, further limiting the reach of diagnostic tools. These factors are anticipated to restrain the silent heart attack market growth during the forecast period.

The continuous advancements and innovations in imaging technologies such as MRI, CT scans, and echocardiography can enhance the detection of subtle myocardial damage characteristic of silent heart attacks. These technologies offer higher resolution and sensitivity, allowing for more accurate identification of tissue abnormalities. Research into specific biomarkers associated with silent heart attacks, such as troponin levels and inflammatory markers, is crucial. Advancements in biomarker detection and interpretation can provide clinicians with more precise tools for early diagnosis and monitoring. Continuous monitoring through wearable devices offers the potential for real-time detection of silent heart attacks or their precursors. Devices capable of monitoring vital signs, ECG patterns, and other relevant metrics can alert individuals and healthcare providers to subtle changes indicative of cardiac issues. These factors are anticipated to create opportunities in the silent heart attack market during the forecast years.

Acts and Initiatives in the Global Silent Heart Attack Market

The market is experiencing rapid growth and transformation, driven by factors such as technological advancements, increasing healthcare costs, aging populations, and the demand for efficient and accessible healthcare services. This market encompasses a wide range of technologies aimed at improving patient care, streamlining operations, and reducing costs across the healthcare industry.

• In the United States, the cardiovascular disease prevention Act (CDPA) was passed to enhance efforts in preventing heart disease, including silent heart attacks. This legislation allocated significant funding to research institutions and public health agencies for developing new diagnostic methods and treatment strategies. Additionally, it mandated regular reporting and analysis of heart attack data to identify trends and improve preventive measures.
• Governments and health organizations have launched public awareness campaigns to educate people about the symptoms of silent heart attacks, which can be subtle or absent compared to typical heart attack symptoms.

Market Segmentation

The silent heart attack market is segmented into diagnosis, treatment, end user, and region. On the basis of diagnosis, the market is divided into computed tomography (CT), electrocardiography (ECG), magnetic resonance imaging (MRI), and blood tests. On the basis of treatment, the market is divided into medications, coronary angioplasty & stenting, and coronary artery bypass surgery. On the basis of end user, the market is divided into hospitals, clinics, and diagnostic centers. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Regional Market Outlook

The United States is the largest market for silent heart attacks, driven primarily by the rising prevalence of cardiovascular diseases and diabetes. According to the Centers for Disease Control and Prevention (CDC), approximately 9.3% of the American population suffers from diabetes. This high prevalence of diabetes contributes significantly to the risk of silent heart attacks, where symptoms are minimal or unrecognized, leading to delayed diagnosis and treatment. The aging population in America is another critical factor contributing to the market growth. Older adults are at a higher risk of both cardiovascular diseases and diabetes, thereby increasing the incidence of silent heart attacks. As the proportion of elderly individuals in the population grows, so does the need for targeted healthcare services to manage and treat age-related health conditions.

On May 13, 2023, UK researchers developed a novel AI-based algorithm to help doctors diagnose heart attacks accurately. Researchers from the University of Edinburgh reported that the new algorithm, CoDE-ACS, ruled out heart attacks in more than double the number of patients with 99.6% accuracy compared to current testing methods.

Competitive Landscape

The major players operating in the silent heart attack market include Siemens, Schiller AG, Midmark Corporation, Koninklijke Philips N.V., Bionet, Welch Allyn, Toshiba Medical Systems Corporation, AstraZeneca plc, Pfizer, and Sanofi.

Recent Key Strategies and Developments

• On November 10, 2023, Amgen revealed new data highlighting the safety and efficacy of Repatha® (evolocumab) from the FOURIER Open Label Extension (OLE) [FOURIER-OLE] trial at the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia. The presentations focused on the reduction of LDL "bad" cholesterol (LDL-C), a known cardiovascular disease (CVD) risk factor. Amgen also presented new research from the Phase 2 OCEAN(a)-DOSE study on its investigational small interfering RNA (siRNA) olpasiran, which targets lipoprotein(a) [Lp(a)], a primarily genetically determined CVD risk factor.
• In June 26, 2024, AliveCor launched the Kardia 12L, a handheld, AI-powered pocket ECG capable of detecting heart attacks.

Key Sources Referred

1. Health Organizations and Foundations
2. American Heart Association (AHA)
3. National Institutes of Health (NIH)
4. World Health Organization (WHO)
5. Centers for Disease Control and Prevention (CDC)

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the silent heart attack market segments, current trends, estimations, and dynamics of the silent heart attack market analysis from 2024 to 2033 to identify the prevailing silent heart attack market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the medical camera market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global silent heart attack market statistics.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

Apart from the points mentioned above, the report includes the analysis of the regional as well as global silent heart attack, key players, market segments, application areas, and market growth strategies.

1. Research Methodology

1.1. Desk Research
1.2. Real time insights and validation
1.3. Forecast model
1.4. Assumptions and forecast parameters
1.5. Market size estimation

1.5.1. Top-down approach
1.5.2. Bottom-up approach

2. Report Scope

2.1. Market definition
2.2. Key objectives of the study
2.3. Market segmentation

3. Executive Summary
4. Market Overview

4.1. Introduction
4.2. Growth impact forces

4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities

4.3. Market value chain analysis

4.3.1. List of raw material suppliers
4.3.2. List of manufacturers 
4.3.3. List of distributors

4.4. Innovation & sustainability matrices

4.4.1. Technology matrix
4.4.2. Regulatory matrix

4.5. Porter’s five forces analysis

4.5.1. Bargaining power of suppliers
4.5.2. Bargaining power of consumers
4.5.3. Threat of substitutes
4.5.4. Threat of new entrants
4.5.5. Competitive Rivalry Intensity

4.6. PESTLE analysis

4.6.1. Political
4.6.2. Economical
4.6.3. Social
4.6.4. Technological
4.6.5. Legal
4.6.6. Environmental

4.7. Impact of COVID-19 on Silent Heart Attack Market  

4.7.1. Pre-covid market scenario
4.7.2. Post-covid market scenario

5. Silent Heart Attack Market Analysis, by Diagnosis

5.1. Overview
5.2. Computed Tomography (CT)

5.2.1. Definition, key trends, growth factors, and opportunities
5.2.2. Market size analysis, by region, 2022-2032
5.2.3. Market share analysis, by country, 2022-2032

5.3. Electrocardiography (ECG)

5.3.1. Definition, key trends, growth factors, and opportunities
5.3.2. Market size analysis, by region, 2022-2032
5.3.3. Market share analysis, by country, 2022-2032

5.4. Magnetic Resonance Imaging (MRI)

5.4.1. Definition, key trends, growth factors, and opportunities
5.4.2. Market size analysis, by region, 2022-2032
5.4.3. Market share analysis, by country, 2022-2032

5.5. Blood Tests

5.5.1. Definition, key trends, growth factors, and opportunities
5.5.2. Market size analysis, by region, 2022-2032
5.5.3. Market share analysis, by country, 2022-2032

5.6. Research Dive Exclusive Insights

5.6.1. Market attractiveness
5.6.2. Competition heatmap

6. Silent Heart Attack Market   Analysis, by Treatment

6.1. Overview
6.2. Medications

6.2.1. Definition, key trends, growth factors, and opportunities
6.2.2. Market size analysis, by region, 2022-2032
6.2.3. Market share analysis, by country, 2022-2032

6.3. Coronary Angioplasty & Stenting

6.3.1. Definition, key trends, growth factors, and opportunities
6.3.2. Market size analysis, by region, 2022-2032
6.3.3. Market share analysis, by country, 2022-2032

6.4. Coronary Artery Bypass Surgery

6.4.1. Definition, key trends, growth factors, and opportunities
6.4.2. Market size analysis, by region, 2022-2032
6.4.3. Market share analysis, by country, 2022-2032

6.5. Research Dive Exclusive Insights

6.5.1. Market attractiveness
6.5.2. Competition heatmap

7. Silent Heart Attack Market   Analysis, by End User

7.1. Overview
7.2. Hospitals

7.2.1. Definition, key trends, growth factors, and opportunities
7.2.2. Market size analysis, by region, 2022-2032
7.2.3. Market share analysis, by country, 2022-2032

7.3. Clinics

7.3.1. Definition, key trends, growth factors, and opportunities
7.3.2. Market size analysis, by region, 2022-2032
7.3.3. Market share analysis, by country, 2022-2032

7.4. Diagnostic Centers

7.4.1. Definition, key trends, growth factors, and opportunities
7.4.2. Market size analysis, by region, 2022-2032
7.4.3. Market share analysis, by country, 2022-2032

7.5. Research Dive Exclusive Insights

7.5.1. Market attractiveness
7.5.2. Competition heatmap

8. Silent Heart Attack Market, by Region

8.1. North America

8.1.1. U.S.

8.1.1.1. Market size analysis, by Diagnosis, 2022-2032
8.1.1.2. Market size analysis, by Treatment, 2022-2032
8.1.1.3. Market size analysis, by End User, 2022-2032

8.1.2. Canada

8.1.2.1. Market size analysis, by Diagnosis, 2022-2032
8.1.2.2. Market size analysis, by Treatment, 2022-2032
8.1.2.3. Market size analysis, by End User, 2022-2032

8.1.3. Mexico

8.1.3.1. Market size analysis, by Diagnosis, 2022-2032
8.1.3.2. Market size analysis, by Treatment, 2022-2032
8.1.3.3. Market size analysis, by End User, 2022-2032

8.1.4. Research Dive Exclusive Insights

8.1.4.1. Market attractiveness
8.1.4.2. Competition heatmap

8.2. Europe

8.2.1. Germany 

8.2.1.1. Market size analysis, by Diagnosis, 2022-2032
8.2.1.2. Market size analysis, by Treatment, 2022-2032
8.2.1.3. Market size analysis, by End User, 2022-2032

8.2.2. UK

8.2.2.1. Market size analysis, by Diagnosis, 2022-2032
8.2.2.2. Market size analysis, by Treatment, 2022-2032
8.2.2.3. Market size analysis, by End User, 2022-2032

8.2.3. France

8.2.3.1. Market size analysis, by Diagnosis, 2022-2032
8.2.3.2. Market size analysis, by Treatment, 2022-2032
8.2.3.3. Market size analysis, by End User, 2022-2032

8.2.4. Spain

8.2.4.1. Market size analysis, by Diagnosis, 2022-2032
8.2.4.2. Market size analysis, by Treatment, 2022-2032
8.2.4.3. Market size analysis, by End User, 2022-2032

8.2.5. Italy

8.2.5.1. Market size analysis, by Diagnosis, 2022-2032
8.2.5.2. Market size analysis, by Treatment, 2022-2032
8.2.5.3. Market size analysis, by End User, 2022-2032

8.2.6. Rest of Europe

8.2.6.1. Market size analysis, by Diagnosis, 2022-2032
8.2.6.2. Market size analysis, by Treatment, 2022-2032
8.2.6.3. Market size analysis, by End User, 2022-2032

8.2.7. Research Dive Exclusive Insights

8.2.7.1. Market attractiveness
8.2.7.2. Competition heatmap

8.3. Asia-Pacific

8.3.1. China

8.3.1.1. Market size analysis, by Diagnosis, 2022-2032
8.3.1.2. Market size analysis, by Treatment, 2022-2032
8.3.1.3. Market size analysis, by End User, 2022-2032

8.3.2. Japan 

8.3.2.1. Market size analysis, by Diagnosis, 2022-2032
8.3.2.2. Market size analysis, by Treatment, 2022-2032
8.3.2.3. Market size analysis, by End User, 2022-2032

8.3.3. India

8.3.3.1. Market size analysis, by Diagnosis, 2022-2032
8.3.3.2. Market size analysis, by Treatment, 2022-2032
8.3.3.3. Market size analysis, by End User, 2022-2032

8.3.4. Australia

8.3.4.1. Market size analysis, by Diagnosis, 2022-2032
8.3.4.2. Market size analysis, by Treatment, 2022-2032
8.3.4.3. Market size analysis, by End User, 2022-2032

8.3.5. South Korea

8.3.5.1. Market size analysis, by Diagnosis, 2022-2032
8.3.5.2. Market size analysis, by Treatment, 2022-2032
8.3.5.3. Market size analysis, by End User, 2022-2032

8.3.6. Rest of Asia-Pacific

8.3.6.1. Market size analysis, by Diagnosis, 2022-2032
8.3.6.2. Market size analysis, by Treatment, 2022-2032
8.3.6.3. Market size analysis, by End User, 2022-2032

8.3.7. Research Dive Exclusive Insights

8.3.7.1. Market attractiveness
8.3.7.2. Competition heatmap

8.4. LAMEA

8.4.1. Brazil

8.4.1.1. Market size analysis, by Diagnosis, 2022-2032
8.4.1.2. Market size analysis, by Treatment, 2022-2032
8.4.1.3. Market size analysis, by End User, 2022-2032

8.4.2. UAE

8.4.2.1. Market size analysis, by Diagnosis, 2022-2032
8.4.2.2. Market size analysis, by Treatment, 2022-2032
8.4.2.3. Market size analysis, by End User, 2022-2032

8.4.3. Saudi Arabia

8.4.3.1. Market size analysis, by Diagnosis, 2022-2032
8.4.3.2. Market size analysis, by Treatment, 2022-2032
8.4.3.3. Market size analysis, by End User, 2022-2032

8.4.4. South Africa

8.4.4.1. Market size analysis, by Diagnosis, 2022-2032
8.4.4.2. Market size analysis, by Treatment, 2022-2032
8.4.4.3. Market size analysis, by End User, 2022-2032

8.4.5. Rest of LAMEA

8.4.5.1. Market size analysis, by Diagnosis, 2022-2032
8.4.5.2. Market size analysis, by Treatment, 2022-2032
8.4.5.3. Market size analysis, by End User, 2022-2032

8.4.6. Research Dive Exclusive Insights

8.4.6.1. Market attractiveness
8.4.6.2. Competition heatmap

9. Competitive Landscape

9.1. Top winning strategies, 2022

9.1.1. By strategy
9.1.2. By year

9.2. Strategic overview
9.3. Market share analysis, 2022

10. Company Profiles

10.1. Siemens
10.1.1. Overview
10.1.2. Business segments
10.1.3. Product portfolio
10.1.4. Financial performance
10.1.5. Recent developments
10.1.6. SWOT analysis

10.2. Schiller AG

10.2.1. Overview
10.2.2. Business segments
10.2.3. Product portfolio
10.2.4. Financial performance
10.2.5. Recent developments
10.2.6. SWOT analysis

10.3. Midmark Corporation

10.3.1. Overview
10.3.2. Business segments
10.3.3. Product portfolio
10.3.4. Financial performance
10.3.5. Recent developments
10.3.6. SWOT analysis

10.4. Koninklijke Philips N.V.

10.4.1. Overview
10.4.2. Business segments
10.4.3. Product portfolio
10.4.4. Financial performance
10.4.5. Recent developments
10.4.6. SWOT analysis

10.5. Bionet

10.5.1. Overview
10.5.2. Business segments
10.5.3. Product portfolio
10.5.4. Financial performance
10.5.5. Recent developments
10.5.6. SWOT analysis

10.6. Welch Allyn

10.6.1. Overview
10.6.2. Business segments
10.6.3. Product portfolio
10.6.4. Financial performance
10.6.5. Recent developments
10.6.6. SWOT analysis

10.7. Toshiba Medical Systems Corporation

10.7.1. Overview
10.7.2. Business segments
10.7.3. Product portfolio
10.7.4. Financial performance
10.7.5. Recent developments
10.7.6. SWOT analysis

10.8. AstraZeneca plc

10.8.1. Overview
10.8.2. Business segments
10.8.3. Product portfolio
10.8.4. Financial performance
10.8.5. Recent developments
10.8.6. SWOT analysis

10.9. Pfizer

10.9.1. Overview
10.9.2. Business segments
10.9.3. Product portfolio
10.9.4. Financial performance
10.9.5. Recent developments
10.9.6. SWOT analysis

10.10. Sanofi

10.10.1. Overview
10.10.2. Business segments
10.10.3. Product portfolio
10.10.4. Financial performance
10.10.5. Recent developments
10.10.6. SWOT analysis

* Taxes/Fees, If applicable will be added during checkout. All prices in USD.